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Abstract
Background: Low testosterone (T), whether due to ovarian and/or adrenal insufficiency, usually results in poor
follicle maturation at small growing follicle stages. The consequence is a phenotype of low functional ovarian
reserve (LFOR), characterized by poor granulosa cell mass, low anti-Müllerian hormone and estradiol but rising
follicle stimulating hormone. Such hypoandrogenism can be of ovarian and/or adrenal origin. Dehydroepiandrosterone
sulfate (DHEAS) is exclusively produced by adrenals and, therefore, reflects adrenal androgen production in the zona
reticularis. We here determined in a case study of infertile women with LFOR the presence of adrenal
hypoandrogenism, its effects on ovarian function, and the possibility of presence of concomitant adrenal insufficiency
(AI), thus reflecting insufficiency of all three adrenal cortical zonae.
Methods: We searched our center’s anonymized electronic research database for women with LFOR, who were also
characterized by peripheral adrenal hypoandrogenemia (total testosterone < 16.9 ng/dL) and low DHEAS (<76.0 μg/dL).
Among 225 women with LFOR, we identified 29 (12.9 %). The adrenal function of so identified women were further
investigated with morning cortisol and ACTH levels and/or standard ACTH stimulation tests. We also determined the
prevalence of classical AI (insufficiency glucocorticoid production by zona fasciculata) in hypoandrogenic women with
LFOR, and impact of adrenal hypoandrogenism on ovaries.
Results: Among 14/28 women with adrenal hypoandrogenism due to insufficiency of the zona reticularis available for
follow up, 4 (28.6 %) also demonstrated previously unrecognized classical primary, secondary or tertiary AI due to
insufficiency of the zona fasciculata. An additional patient with presenting diagnosis of seemingly primary ovarian
insufficiency (POI), demonstrated extremely low T and DHEAS levels, a diagnosis of Addison’s disease, and was on
glucocorticoid but not androgen supplementation. As her dramatic improvement in ovarian function criteria after
androgen supplementation confirmed, her correct diagnosis, therefore, was actually secondary ovarian insufficiency
(SOI) due to adrenal hypoandrogenism.
Conclusions: Women with LFOR, characterized by low T and DHEAS, are also at risk for AI, while women with AI may
be at risk for adrenal induced hypoandrogenism and, therefore, SOI. A currently undetermined percentage of POI
patients actually are, likely, affected by SOI, a for prognostic reasons highly significant difference in diagnosis.
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Background
For many years hypoandrogenemia has been recognized
as a characteristic feature of primary ovarian insufficiency
(POI) [1]. More recently, low testosterone (T) levels have
also been reported in association with milder cases of
POI, so called occult POI (oPOI), characterized by low
(age specific) functional ovarian reserve (LFOR) [2].
Over the last decade various animal models and clin-
ical human experience have provided increasing evi-
dence that T is essential for normal follicle growth and
maturation during small growing follicle stages. Insuffi-
cient androgen receptor (AR) activity on granulosa cells
leads to poorer growth of fewer follicles, and to poor oo-
cyte quality in surviving follicles [3].
Albeit still controversial [4, 5], these observations have
led to androgen supplementation in women with
hypoandrogenic LFOR [6], and to the suggestion that
pregnancy success with in vitro fertilization (IVF) in
hypoandrogenic LFOR directly correlates with improve-
ments in patients’ testosterone levels [7].
Ovaries (theca cells) and adrenals (zona reticularis)
produce the majority of androgens. Consequently, like
hyperandrogenism in association with polycystic ovary
syndrome (PCOS) [8], hypoandrogenism can be of ovar-
ian and/or adrenal etiology. Though accurate differenti-
ation is not always possible, it is generally accepted that
low dehydroepiandrosterone sulfate (DHEAS), almost
exclusively produced by the zona reticularis of adrenals,
in association with low testosterone levels, strongly sug-
gests adrenal origin of low androgen levels [9–11].
We recently discovered that, as reflection of adrenal
function, peripheral androgen precursor levels in infer-
tile women with LFOR correlate with morning cortisol
[12]. This observation suggests that adrenal and ovarian
functions may to a degree be interdependent. Such inter-
dependency is also supported by the common embryonic
primordium of adrenals and ovaries [13].
We, therefore, in this study investigated this inter-
dependence of adrenals and ovaries based on the recent
recognition that LFOR, independent of cause, is usually
characterized by peripheral hypoandrogenemia [2]. Based
on the presumed origin of patients’ hypoandrogenemia,
we then further assessed adrenal function under the
hypothesis that adrenal origin of hypoandrogenemia
(zona reticularis) may also raise the specter of adrenal
insufficiency (AI) in the other two layers of the ad-
renal cortex.
As further evidence for the hormonal interrelationship
of adrenals and ovaries, we here report four cases of pre-
viously unknown AI in hypoandrogenic women with
LFOR and one case of known primary AI (Addison’s
disease), which was treated with glucocorticoid but not
androgen supplementation and, therefore, presented
with secondary ovarian insufficiency (SOI) due to AI
This case had previously been erroneously diagnosed as
primary ovarian insufficiency (POI).
Methods
Our center maintains an anonymized electronic research
database, which includes patients who consent to use of
their medical records for research purposes as long as
those remain confidential and the patients’ anonymity is
maintained. Use of this electronic database was approved
by our center’s IRB for this study (IRB of The Center for
Human Reproduction, Neil Rosenberg, MD, Chairman,
IRB application number ER0330215/01). All patients
reported here gave written consent for use of their
medical records.
We identified in this database 225 infertile patients
with LFOR, defined as follicle stimulating hormone
(FSH) above, and/or anti-Müllerian hormone (AMH)
below, age-specific 95 % CI [14, 15]. To identify women
with potential adrenal hypoandrogenism, we further
searched among LFOR patients for those with abnor-
mally low total testosterone (TT). We selected TT rather
than free testosterone (FT) to define the study popula-
tion because TT levels have been demonstrated to mar-
ginally better reflect IVF outcomes than FT [7].
Abnormally low TT was defined as the lower third of
normal laboratory range (<16.0 ng/dL)], while abnor-
mally low DHEAS was defined as below the 15th per-
centile of normal laboratory range (<76 μg/dL). Both
cut offs have been used in the context of LFOR in-
vestigations before [2, 12]. All androgen assays were
performed utilizing liquid chromatography/tandem mass
spectrometry.
Among 29 women with low TT and DHEAS, 14
were available for follow up assessments of adrenal
function with morning cortisol (C) and adrenocortico-
tropin (ACT) levels and/or full 2-h ACTH stimulation
tests. The other 15 patients either could not be
reached or refused participation in this follow up.
Morning C was considered abnormally low at levels
of < 5.0 μg/dL, while ACTH was considered abnor-
mally high at > 100 pg/mL. C and ACTH levels were
obtained by commercial assays. Adrenocorticotropin
hormon stimulation was performed with Cortrosyn®
(cosyntropin, Amphastar Pharmaceuticals, Inc), 0.25 mg
in routine fashion, with cortisol levels determined at 30
and 60 min. and recently described [16, 17].
Adrenal insufficiency is defined as the inability of
the adrenal cortex to produce sufficient amounts of
glucocorticoids and/or mineralocorticoids [16, 18].
Abnormally low cortisol, by lowering feedback, in-
duces increased stimulation of the adrenal cortex by
(ACTH), which disrupts adrenal production of miner-
alocorticoids, leads to increased plasma renin release
by the juxtaglomerular cells of the kidney and the
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well-known symptomatology of primary AI. Abnormally
high ACTH concentrations are important not only be-
cause of their disruptive effects on the adrenal cortex but
also because they allow differentiation of primary from
secondary AI, with the latter characterized by abnormally
low ACTH levels and, therefore, absence of secondary
clinical effects of excessive ACTH stimulation [18].
Results
Out of 14 patients identified with likely adrenal hypoan-
drogenism, 10 were found to demonstrate entirely nor-
mal adrenal function. Table 1 summarizes the clinical
presentations of four who as part of this study for the
first time received a diagnosis of AI. One patient was di-
agnosed with primary AI, two were diagnosed with sec-
ondary AI and a fourth with tertiary AI.
The case of tertiary AI was a long standing systemic
lupus erythematosus (SLE) patient on corticosteroid
therapy who also suffered from long standing infertility.
Though she had failed a prior in vitro fertilization
(IVF) cycle, she spontaneously conceived once her an-
drogens were supplemented with dehydroepiandros-
terone (DHEA) normalizing her abnormally low TT
and excessively high sex hormone-binding globulin
(SHBG) levels.
We in addition identified a 41-year-old female with
established Addison’s disease (primary AI) on gluco-
corticoid replacement who was not being supplemented
with androgens. She based on a greatly elevated FSH
level of 44.0 mIU/mL presented with diagnosis of POI.
Her TT, FT, DHEA and DHEAS were all below lower
cut off levels of normal range, while her SHBG was
above normal range. She, thus, with great likelihood
demonstrated adrenal hypoandrogenism. Once supple-
mented with DHEA (25 mg TID), her androgens nor-
malized and her FSH level declined to 14.8 mIU/mL.
Table 1 Characteristics of 4 patients diagnosed with previously unknown AI among women with adrenal hypoandrogenemia*
Patient Age
(years)
Diagnoses Laboratory Final diagnosis








1 28 POI1 Hypothyroid +TPO2 30.0 3.04 TT 7.0 ng/dL 464.7 8.8 Primary AI
+ TG3 14.4 2.12 TT ud6
Celiac + DG4 DHEA ud
+ TG5 DHEAS ud
2 30 PCOS SLE7 8.0 2.68 FT 0.4 pg/mL ** Likely iatrogenic AI
HNA8 TT 17.0 ng/dL
DHEA 273.0 ng/dL
DHEAS ud
*** 4.11 TT 30.0 ng/dL
DHEA 272.0ug/dL
3 30 7.7 ud DHEAS 70.0ug/dL ud 1.4 Secondary AI as part of
pan- hypo-pituitarism
8.7 ud FT 1.4 pg.mL 1.7
TT 14.0 ng/dL
DHEAS 56ug/dL




1POI primary ovarian insufficiency; 2TPO thyroid peroxidase antibody; 3TG thyroglobulin antibody; 4DG deamidated gliadin antibody (IgA); 5TG t-transglutaminase
(igA) antibody; 6ud undetectable; 7SLE systemic lupus erythematosus treated with 7 mg prednisone p.o. o.d.; 8HNA non-heredetary angioedema
*Only 14 of 29 women identified in the center’s research database with adrenal hypoandrogenemia have so far been investigated in follow up
** Not obtained since patients received long-term prednisone
*** Androgens and AMH level after supplementation with DHEA
Patient 1: Upon diagnosis with PAI, the patient initiated supplementation with hydrocortisone, and continued her supplementation with levothyroxine. Though
this patient presented to our center with a diagnosis of POI, her FSH values did not support this diagnosis but a diagnosis of oPOI/POA
Patient 2: This patient consulted long-distance with our center after a spontaneous pregnancy loss in a spontaneously conceived pregnancy and after an IVF cycle
suggestive of PCOS (29 oocytes), but with only 2 poor-quality embryos. After low androgens were noted, we recommended supplementation with DHEA 25 mg
p.o., t.i.d. Androgen levels improved, as did her AMH, and the patient spontaneously conceived what was diagnosed as an ectopic pregnancy. We suspect this to
represent a case of iatrogenic (tertiary) AI, secondary to prolonged prednisone supplementation
Patient 3: This patient presented to our center since us of a gestational carrier had been recommended to her elsewhere
Patient 4: This patient presented with primary infertility and Crohn’s disease, treated with Enbrel® (etanercept)
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This patient’s presenting diagnosis of POI was, there-
fore, incorrect; a consequence adrenal hypoandrogenism
of the zona reticularis, she really suffered from SOI,
which apparently was part of a mixed adrenal cortex in-
sufficiency of the zona fasciculata (leading to Addison’s
disease) and the zona reticularis (leading to SOI).
Discussion
Adrenal insufficiency (AI) is a complex, at times life
threatening disease, which can be the result of failure of
the adrenal glands (primary AI), can be consequence of
failure of the hypothalamic/pituitary axis (secondary AI)
or can be iatrogenic (tertiary AI) [16, 18]. We here re-
port on four (out of 14) women with adrenal hypoandro-
genism (low T and low DHEAS), who, upon adrenal
evaluation, were found to suffer from AI, -one case of
primary, two cases of secondary and one case of tertiary
AI.
We also discovered among those patient one woman
who already had been diagnosed with Addison’s disease
(primary AI) and received glucocorticoid supplementa-
tion. Her treating physician was, however, unaware that,
due zona reticularis insufficiency, she also was severely
hypoandrogenic. With definition of AI currently restricted
to insufficiency of zona fascilulata (glucocorticoids) and
zona glomerulosa (mineralocorticoids), adrenal hypoan-
drogenism of the zona reticularis is, interestingly, excluded
from the diagnosis of AI [16, 18].
In presence of severe hypoandrogenism (all of her
androgen values were significantly below the lower cut
offs of normal range), testosterone-dependent small
growing follicle stages [3], likely, arrested. As a
consequence, granulosa cell mass and estradiol produc-
tion declined, AMH levels dropped and FSH increased
due to diminished feed back on the pituitary, leading to
what can be easily mistaken for a fairly typical clinical
POI phenotype (Fig. 1). Due to its adrenal origin, it,
however, really represents a form of SOI.
With 4/14 women diagnosed with a form of AI, we
here report an unexpectedly high, and likely exaggerated
prevalence of AI in infertile women with hypoandro-
genic LFOR of adrenal etiology. Further, larger scale
studies are obviously needed to assess the true preva-
lence. However, even here presented small case series
suggests that in such women a careful adrenal evaluation
appears indicated.
Here presented data in addition suggest that AI may
not only include insufficiencies of zona fasciculate and
zona glomerulosa but also also of the zona reticularis,
leading to adrenal hypoandrogenism. Therefore, one also
has to conclude that, at least in women of reproductive
years, assessments of peripheral androgens appear indi-
cated if AI is suspected or already diagnosed.
POI is classically associated with hypoandrogenism
[1, 2], usually primarily the consequence of insuffi-
cient T production of ovarian theca cells. POI, there-
fore, represents true ovarian insufficiency/aging, while
in cases of SOI, once adrenal hypoandrogenism is appro-
priately supplemented, ovarian function may normalize,
and responses to pharmacological stimulation of ovar-
ies may improve. Figure 1 explains the underlying
pathophysiology.
Correct differential diagnoses between POI and SOI
are, therefore, of importance since a diagnosis SOI often
Fig. 1 Control of ovarian function via adrenal androgen production. *Under ovarian stimulation with gonadotropin very high; The figure depicts
how androgen production in the zona reticularis of the adrenals can affect ovarian function: With low androgen production (for example
insufficient capacity to sulfonize DHEA to DHEAS), growth and development of small growing follicles in ovaries (also called the functional
ovarian reserve, FOR) is inhibited. LFOR develops, resulting in low estradiol and AMH levels due to declining granulosa cell mass. Due to
decreasing feedback via estradiol, FSH production in the pituitary increases, leading to typically elevated FSH levels, usually attributed to a POI
phenotype. These cases, however, actually represent a secondary form of ovarian insufficiency (SOI), primarily driven by adrenal hypoandrogenism. At
the opposite extreme of ovarian function, androgen production by the adrenal cortex is responsible for some cases of PCOS
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reflects a much better prognosis. We, in SOI, indeed,
have seen relative normalization of abnormally high FSH
levels (Patient 2 in Table 1 and above noted patient with
previously known Addison’s disease), and in Patient 2
even encountered a spontaneous pregnancy following
normalization of T and SHBG levels after DHEA supple-
mentation. Such radical changes for the better in ovarian
phenotype will practically never be witnessed in cases of
POI.
As in women with polycystic ovarian syndrome (PCOS),
relative contributions to hyperandrogenisms of adrenals
and ovaries are at times difficult to separate [8], so are in
women with LFOR contributions to low T. During ste-
roidogenesis, DHEA is via sulfotransferase converted to
DHEAS (its 3β-sulfate), a conversion almost exclusively
coded by the SULT2A1 gene. Sult2A1 is, however, highly
expressed only in the zona reticularis of the adrenal cor-
tex, and practically absent in ovarian tissue [9–11]. If
DHEAS is also abnormally low, low T in women can,
therefore, be assumed to be of adrenal origin.
A few more words about the relevance of AI to ovar-
ian function: Though the underlying pathophysiology for
this association has remained unresolved, primary AI
has been associated with female infertility for decades.
[19]. Here suggested pathophysiology of SOI offers a
possible explanation.
In developed countries over 90 % of primary AI is con-
sidered autoimmune in etiology, frequently coexisting
with other autoimmune endocrinopathies [18, 20]. Inter-
estingly, the only so far histopathologically defined auto-
immune condition of ovaries in humans, so-called
autoimmune oophoritis, practically exclusively only oc-
curs in association with primary AI. This dependency
strongly suggests common immunologic epitopes in adre-
nals and ovaries as targets of shared autoimmune attacks,
possibly representing steroidogenic enzymes [21, 22].
Autoantibodies to 21-hydroxylase are widely considered
diagnostic of primary AI, and are accepted as evidence for
the autoimmune etiology of AI. These autoantibodies, in-
deed, often precede diagnosis of the disease [18, 23], and
approximately 30 % of asymptomatic individuals with
positive 21-hydroxylase antibodies will progress to clinical
primary AI within five years [24].
Why is this important within here presented discussion?
Addison’s disease can also occur in absence of 21-
hydroxylase antibodies, though such cases are rare ex-
cept in young children and the elderly [15]. Other than
21-hydroxylase, yet unknown antibodies to steroidogenic
enzymes and/or other common epitopes between adre-
nals and ovaries may, therefore, also play an important
role in anti-adrenal and anti-ovarian autoimmunity.
Autoantibodies to other steroidogenic enzymes have, in-
deed, been reported [22], though, currently are not con-
sidered diagnostic of primary AI.
Autoimmunity to endocrine glands is a commonly ob-
served phenomenon; many such attacks, indeed, occur
in combinations [20]. It, therefore, is difficult to imagine
that anti-adrenal autoimmunity can affect only zona fas-
ciculate and zona granulosa but will not affect the zona
reticularis. For that reason, it appears somewhat puz-
zling that an autoimmune attack on the androgen-
producing zona reticularis is currently not considered a
possibility in AI. It appears more reasonable to assume
that all three zones of the adrenal cortex can be subjects
of autoimmune attacks, sharing risks and manifesting
different combinations of involvement. Patients with
glucocorticoid deficiency for that reason have to be
monitored for the development of mineralocorticoid
deficiencies [18]. Here presented study supports the con-
tention that the zona reticularis should also be consid-
ered as a potential target of adrenal autoimmunity in
presence of autoimmune attacks against the other two
zonae.
In the developed world, in absence of tuberculosis and
trauma, AI is, practically universally, considered an auto-
immune condition [25]. Low T due to adrenal causes,
therefore, with great likelihood has also to be considered
autoimmune.
Finally, here discussed findings may also have rele-
vance for the PCOS, increasingly viewed as the opposing
extreme of LFOR on a spectrum of ovarian function
[20]: While LFOR is hypoandrogenic [1, 2] and associ-
ated with low follicle yields, PCOS typically presents
with high T, excessive follicle recruitment and, therefore,
high FOR. At excessively high T levels, follicles, however,
arrest at preantral stages [26]. Adrenal androgen produc-
tion thus influences ovarian function over a wide range,
from SOI to secondary PCOS (Fig. 1).
Conclusions
We, therefore, conclude that, functionally, adrenals and
ovaries have increasingly to be viewed as a single endo-
crine unit. The common developmental primordium
(primordial germ cells) of adrenals and gonads is sup-
portive of such a concept [13].
This study further strengthens recently reported evi-
dence that adrenal glands and ovaries closely interact
in regulating ovarian function via shared androgen
production, which, in turn, affects follicle maturation
in ovaries. This study, in addition, however, for the
first time also demonstrates mutual diagnostic de-
pendencies: LFOR in women of reproductive age, es-
pecially if associated with relative hypoandrogenism of
adrenal origin (characterized by low DHEAS), should be
seen as an indication for adrenal function evaluation. Con-
comitantly, a diagnosis of AI in women in reproductive
years should immediately be considered an indication for
evaluation FOR in the patient.
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